BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Takeda Announces Chief Financial Officer Succession

  Takeda announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family.

  February 1, 2024

   · 

  8 min read
• Business

  HUTCHMED to Announce 2023 Final Results

  HUTCHMED Limited will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time / 11:30 am Greenwich Mean Time / 7:30 pm Hong Kong Time.

  February 1, 2024

   · 

  1 min read
• Business

  Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

  Maxion Therapeutics announced that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development.

  February 1, 2024

   · 

  4 min read
• Policy

  FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

  Fennec Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has issued a public reminder to healthcare providers that PEDMARK is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label.

  February 1, 2024

   · 

  2 min read
• Business

  West to Host Fourth-Quarter and Full-Year 2023 Conference Call

  West Pharmaceutical Services, Inc. announced that it will release fourth-quarter and full-year 2023 financial results before the market opens on Thursday, February 15, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

  February 1, 2024

   · 

  2 min read
• Biotech Beach

  Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

  Revelation Biosciences Inc. announced the pricing of a public offering of 1,365,000 shares of its common stock, together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of $4.53 per share and associated warrant.

  February 1, 2024

   · 

  5 min read
• Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

  To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization, has expanded its DMPK capabilities.

  February 1, 2024

   · 

  3 min read
• Policy

  Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

  Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.

  February 1, 2024

   · 

  2 min read
• LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

  LimmaTech Biologics announced a second closing of its Series A financing, raising an additional USD 3 million from new investor Tenmile, bringing the total raised to USD 40 million.

  February 1, 2024

   · 

  3 min read
• Business

  Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer

  Resalis Therapeutics announced the appointment of Almut Nitsche, PhD, as its Chief Medical & Development Officer.

  February 1, 2024

   · 

  2 min read